Trade Summary

6 days ago, Kumar Neil, serving as CEO at Bridgebio Pharma, Inc. (BBIO), sold 80,000 shares at $67.40 per share, for a total transaction value of $5,392,243.00. Following this transaction, Kumar Neil now holds 5,148,584 shares of BBIO.

This sale represents a 2.00% decrease in Kumar Neil's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Thursday, May 7, 2026 and publicly disclosed via SEC Form 4 filing on Monday, May 11, 2026, 4 days after the trade was made.

Bridgebio Pharma, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.